Effect of magnesium supplementation on carotid intima-media thickness and flow-mediated dilatation among hemodialysis patients: a double-blind, randomized, placebo-controlled trial.
Study Goal
The researchers aimed to determine the effect of magnesium supplementation on endothelial function, including its potential role in regulating calcium and phosphorus levels in hemodialysis patients.
Results Summary
The study found that magnesium supplementation significantly reduced carotid intima-media thickness (cIMT), a marker of atherosclerosis, possibly due to its regulation of parathormone, calcium, and phosphorus. However, it did not improve other endothelial function markers like CRP levels or brachial artery flow-mediated dilatation (FMD).
Population
Hemodialysis patients (n=54)
Effective Dosage
440 mg of magnesium oxide, 3 times per week
Duration
6 months
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
oral magnesium (Mg) supplementation | decrease | carotid intima-media thickness (cIMT) | hemodialysis (HD) patients | 0.84 ± 0.13 mm at baseline and 0.76 ± 0.13 mm at 6 months | significantly decreased | #1 |
placebo | increase | carotid intima-media thickness (cIMT) | hemodialysis (HD) patients | 0.73 ± 0.13 and 0.79 ± 0.12 mm | significantly increased | #2 |
oral magnesium (Mg) supplementation | no change | endothelial function (CRP level and FMD) | hemodialysis (HD) patients | - | might not improve | #3 |
oral magnesium (Mg) supplementation | decrease | cIMT as a marker of atherosclerosis | hemodialysis (HD) patients | - | decreased | #4 |
OBJECTIVES: The aim of the present study was to determine the efficacy of oral magnesium (Mg) supplementation on endothelial function through evaluation of carotid intima-media thickness (cIMT), brachial artery flow-mediated dilatation (FMD), and C-reactive protein (CRP) among hemodialysis (HD) patients. METHODS: This randomized, controlled, double-blind clinical trial consisted of 54 patients on HD. One group was treated orally with 440 mg of Mg oxide 3 times per week for 6 months (n = 29). The control group (n = 25) was given placebo using the same administration protocol. cIMT, FMD, serum calcium levels, phosphorus, lipid, CRP, and bicarbonate were measured at baseline and at 6 months in both groups. RESULTS: At 6 months, cIMT was significantly decreased in the Mg group (0.84 ± 0.13 mm at baseline and 0.76 ± 0.13 mm at 6 months, p = 0.001). However, in the placebo group, cIMT was significantly increased (0.73 ± 0.13 and 0.79 ± 0.12 mm, respectively, p = 0.003). When hypertension, diabetes mellitus, smoking, hyperlipidemia, and systemic lupus erythematosus were controlled for in the analysis, the effect of Mg remained significant in both groups (p = 0.000). CONCLUSION: Our results indicate that Mg might not improve endothelial function (CRP level and FMD) and that a decreased cIMT as a marker of atherosclerosis may be due to the inhibition of calcification through the regulation parathormone, calcium, and phosphorus.